Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines Corp. (BPMC)
:BPMC
Holding BPMC?
Track your performance easily
BPMC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$72.24 - $121.90
Previous CloseN/A
Volume168.58K
Average Volume (3M)604.86K
Market Cap
$5.76B
Enterprise Value$5.86B
Total Cash (Recent Filing)$214.16M
Total Debt (Recent Filing)$4.31M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Feb 13, 2025EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding63,525,837
10 Day Avg. Volume511,818
30 Day Avg. Volume604,857
Standard Deviation0.13
R-Squared0.06
Alpha0.00321
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.80
Price to Cash Flow (P/CF)-109.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue13.49
Enterprise Value/Gross Profit24.34
Enterprise Value/Ebitda-55.21
Forecast
1Y Price Target
$122.58Price Target Upside35.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Blueprint Medicines News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSuccessfully showcasing a working dose that completely suppresses disease-causing cells positions Blueprint Medicines well for future developments.
Investment OpportunityBlueprint shares represent an attractive investment opportunity at current levels with a global peak revenue opportunity of >$2B in SM and a strong cash position of $882.4MM.
Market ExpansionMachine learning models could potentially increase the diagnoses rate of either ASM or ISM in the primary care setting, which could help expand the addressable market.
Bears Say
Drug Side EffectsBlueprint's avapritinib has shown higher rates of periorbital edema and cognitive side effects in ASM, with rates ranging from 48% to 55% and 11% to 25% respectively.
Market CompetitionThe competitive landscape includes several companies developing similar therapies, which could impact Blueprint Medicines' market position.
Patient GrowthThe new patient iSM adds were down 58% from the 189 new patients estimated in 2Q to 81 new patients in 3Q, suggesting a significant slowdown.
---
Ownership Overview
1.53% Insiders
42.63% Mutual Funds
0.03% Other Institutional Investors
38.36% Public Companies and Individual Investors
BPMC FAQ
What was Blueprint Medicines Corp.’s price range in the past 12 months?
Blueprint Medicines Corp. lowest stock price was $72.24 and its highest was $121.90 in the past 12 months.
What is Blueprint Medicines Corp.’s market cap?
Blueprint Medicines Corp.’s market cap is $5.76B.
When is Blueprint Medicines Corp.’s upcoming earnings report date?
Blueprint Medicines Corp.’s upcoming earnings report date is Feb 13, 2025 which is in 34 days.
How were Blueprint Medicines Corp.’s earnings last quarter?
Blueprint Medicines Corp. released its earnings results on Oct 30, 2024. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$0.961 by $0.071.
Is Blueprint Medicines Corp. overvalued?
According to Wall Street analysts Blueprint Medicines Corp.’s price is currently Undervalued.
Does Blueprint Medicines Corp. pay dividends?
Blueprint Medicines Corp. does not currently pay dividends.
What is Blueprint Medicines Corp.’s EPS estimate?
Blueprint Medicines Corp.’s EPS estimate is -0.7.
How many shares outstanding does Blueprint Medicines Corp. have?
Blueprint Medicines Corp. has 63,525,837 shares outstanding.
What happened to Blueprint Medicines Corp.’s price movement after its last earnings report?
Blueprint Medicines Corp. reported an EPS of -$0.89 in its last earnings report, beating expectations of -$0.961. Following the earnings report the stock price went up 7.002%.
Which hedge fund is a major shareholder of Blueprint Medicines Corp.?
Among the largest hedge funds holding Blueprint Medicines Corp.’s share is Woodline Partners LP. It holds Blueprint Medicines Corp.’s shares valued at 42M.
---
Blueprint Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$122.58 (35.25% Upside)
$122.58 (35.25% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 768.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.23%
12-Months-Change
Fundamentals
Return on Equity
-40.89%
Trailing 12-Months
Asset Growth
8.54%
Trailing 12-Months
Company Description
Blueprint Medicines Corp.
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
BPMC Company Deck
---
BPMC Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial and operational performance for Blueprint Medicines, highlighted by significant revenue growth and strategic advancements in the pipeline. Despite some challenges with pricing dynamics in the international markets and potential impacts of free drug policies, the overall outlook remains positive with a focus on sustainable growth and innovation.Read More>---
BPMC Stock 12 Month Forecast
Average Price Target
$122.58
▲(35.25% Upside)
Technical Analysis
Alnylam Pharma
―
FibroGen
―
Revolution Medicines
―
RegenXBio
―
Kura Oncology
―
Sarepta Therapeutics
―
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+15.86%
assigned a buy rating 2 months ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +15.86% per trade.
---